Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 147.45 -0.01 (-0.01%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 Next > NASDAQ:NBIX is not too expensive for the growth it is showing. February 06, 2024 While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable. Via Chartmill Unveiling 13 Analyst Insights On Neurocrine Biosciences January 23, 2024 Via Benzinga NASDAQ:NBIX, a growth stock which is not overvalued. January 15, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. Via Chartmill NASDAQ:NBIX, a strong growth stock, setting up for a breakout. January 12, 2024 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. Via Chartmill Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily Analyst Expectations for Neurocrine Biosciences's Future December 07, 2023 Via Benzinga NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. November 23, 2023 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. Via Chartmill NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. November 07, 2023 Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. Via Chartmill VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today January 02, 2024 VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. Via InvestorPlace Amgen Stock Sees Relative Strength Rating Improve To 74 December 29, 2023 Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. Via Investor's Business Daily Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. Via MarketBeat Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study December 28, 2023 On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. Via Investor's Business Daily Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark December 28, 2023 On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. Via Investor's Business Daily Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher December 26, 2023 On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. Via Investor's Business Daily 3 Stocks at the Forefront of Medical Innovation December 25, 2023 Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. Via InvestorPlace NASDAQ:NBIX—Positioned as a High-Growth Stock, Ready for a Potential Breakout. December 22, 2023 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. Via Chartmill Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. December 22, 2023 While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. Via Chartmill Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade December 21, 2023 On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. Via Investor's Business Daily The 3 Most Undervalued Biotech Stocks to Buy in December December 15, 2023 Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. Via InvestorPlace Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days December 13, 2023 Cassava Sciences sees its Relative Strength Rating reach the 80-plus level. Via Investor's Business Daily Are These Biotechs Ready To Launch? December 09, 2023 Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... Via Talk Markets TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating December 07, 2023 TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. Via Investor's Business Daily Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise December 06, 2023 Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Via Investor's Business Daily Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX. December 01, 2023 Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News November 17, 2023 CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. Via Investor's Business Daily Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating November 17, 2023 Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. Via Investor's Business Daily Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade November 10, 2023 Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. Via Investor's Business Daily Why Is Neurocrine Biosciences Stock Trading Lower Today? November 10, 2023 Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) Via Benzinga 3 Biotech Moonshots to Bet on the Future of Health November 06, 2023 Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Rocket Pharmaceuticals Stock Sees Improved Price Strength November 02, 2023 On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.